SCHEMBL2138190

SCHEMBL2138190

COc1ncccc1-c1nc(C(=O)Nc2ccccc2C(N)=O)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.52
IRAK4 Q9NWZ3 5/20 0.51
TLR7 Q9NYK1 9/20 0.49
ACHE P22303 2/20 0.48
MAOA P21397 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
PRKD3 O94806 1/20 0.43
PRKCG P05129 1/20 0.43
PRKCB P05771 1/20 0.43
IL1R1 P14778 1/20 0.43
PRKCA P17252 1/20 0.43
TNFRSF1A P19438 1/20 0.43
PRKCH P24723 1/20 0.43
PRKCI P41743 1/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCZ Q05513 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2138509 0.80 CHEK1 (0.59) IRAK4TLR7NPC1RAB9A
SCHEMBL2140404 0.79 IRAK4 (0.55) IRAK4TLR7NPC1RAB9ACDC25A
SCHEMBL18427815 0.78 TDP1 (0.65) IRAK4TLR7NPC1RAB9A
SCHEMBL2771222 0.77 RAB9A (0.60) IRAK4ACHENPC1RAB9A
SCHEMBL2138888 0.77 IRAK4 (0.74) IRAK4TLR7NPC1RAB9A
SCHEMBL1828736 0.75 TLR7 (0.59) IRAK4TLR7CDC25ACDC25BPOLB
SCHEMBL2919406 0.74 IRAK4 (0.52) IRAK4TLR7ACHENPC1RAB9A
SCHEMBL13162020 0.74 IRAK4 (0.59) IRAK4TLR7NPC1RAB9ACDC25A
SCHEMBL1828125 0.74 PDCD1 (0.49) IRAK4ACHENPC1RAB9APOLB
SCHEMBL9604339 0.74 IRAK4 (0.52) IRAK4TLR7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP claimed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US claimed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US claimed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP claimed
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP disclosed
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
EP-2231652-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Schering Pharma Aktiengesellschaft (DE) 2010-09-29 EP disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
WO-2009074246-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 WO disclosed
WO-2009074246-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 WO disclosed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS CNR2, CYP11B2, CYP2C19 PIM1 3500/4885IRAK4 788/4885TLR7 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.